Valuation : Zai Lab Limited

Market Cap 2.71B 2.34B 2.21B 2B 3.76B 259B 3.78B 26.26B 10.1B 132B 10.18B 9.95B 416B P/E 2026 *
-10.9x
P/E 2027 * -10.9x
Enterprise Value 2.25B 1.94B 1.84B 1.67B 3.12B 215B 3.14B 21.82B 8.39B 109B 8.46B 8.27B 346B EV / Sales 2026 *
5.16x
EV / Sales 2027 * 4.22x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-7.08%
Current month-3.67%
1 month-7.08%
3 months+40.00%
6 months+26.51%
Current year+40.94%
1 week 20.8
Extreme 20.8
22.6
1 month 20.8
Extreme 20.8
23.6
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
116
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.08%-23.91%-14.63% 2.71B
-1.48%-5.59%+37.54%-6.24% 78.02B
-1.42%-4.24%-18.81%-37.78% 57.4B
+5.38%-1.09%+467.03%+36.08% 57.48B
-0.56%-2.21%-11.17%+25.38% 48.81B
+1.93%-2.37%-2.00%+149.45% 45.5B
+0.80%-1.67%+45.89%-16.13% 32.08B
-1.47%-4.17%+40.97%+88.59% 24.62B
-0.85%-8.64%-3.66%+144.26% 20.77B
-0.09%-3.61%+63.58%+97.66% 15.75B
Average +0.25%-3.87%+59.55%+46.66% 42.27B
Weighted average by Cap. +0.38%-3.71%+81.95%+35.53%

Financials

2026 *2027 *
Net sales 436M 376M 356M 323M 606M 41.7B 609M 4.23B 1.63B 21.21B 1.64B 1.6B 67.03B 552M 476M 450M 408M 766M 52.75B 770M 5.35B 2.06B 26.84B 2.07B 2.03B 84.8B
Net income -241M -207M -196M -178M -334M -22.99B -336M -2.33B -897M -11.7B -904M -884M -36.96B -211M -182M -172M -156M -293M -20.17B -294M -2.05B -786M -10.26B -793M -775M -32.42B
Net Debt -458M -394M -373M -338M -635M -43.72B -638M -4.43B -1.71B -22.24B -1.72B -1.68B -70.29B -381M -328M -311M -282M -528M -36.38B -531M -3.69B -1.42B -18.51B -1.43B -1.4B -58.49B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
26-09-11 €21.00 0.00%
26-09-10 €21.00 -3.67%
26-09-09 €21.80 -1.80%
26-09-08 €22.20 -0.89%
26-09-07 €22.40 -0.88%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.14USD
Average target price
33.14USD
Spread / Average Target
+37.28%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!